212 related articles for article (PubMed ID: 28429280)
1. Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
Yuan J; Llamas Luceño N; Sander B; Golas MM
Cell Oncol (Dordr); 2017 Jun; 40(3):263-279. PubMed ID: 28429280
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
3. Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
Patties I; Kortmann RD; Menzel F; Glasow A
J Exp Clin Cancer Res; 2016 Jun; 35(1):94. PubMed ID: 27317342
[TBL] [Abstract][Full Text] [Related]
4. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Luszczek W; Cheriyath V; Mekhail TM; Borden EC
Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
[TBL] [Abstract][Full Text] [Related]
5. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines.
Patties I; Kortmann RD; Glasow A
J Exp Clin Cancer Res; 2013 May; 32(1):27. PubMed ID: 23672687
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice.
Ecke I; Petry F; Rosenberger A; Tauber S; Mönkemeyer S; Hess I; Dullin C; Kimmina S; Pirngruber J; Johnsen SA; Uhmann A; Nitzki F; Wojnowski L; Schulz-Schaeffer W; Witt O; Hahn H
Cancer Res; 2009 Feb; 69(3):887-95. PubMed ID: 19155313
[TBL] [Abstract][Full Text] [Related]
9. Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists.
Jaeger M; Ghisleni EC; Fratini L; Brunetto AL; Gregianin LJ; Brunetto AT; Schwartsmann G; de Farias CB; Roesler R
Childs Nerv Syst; 2016 Jan; 32(1):61-4. PubMed ID: 26590027
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
11. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
Nör C; de Farias CB; Abujamra AL; Schwartsmann G; Brunetto AL; Roesler R
Childs Nerv Syst; 2011 Jun; 27(6):897-901. PubMed ID: 21560052
[TBL] [Abstract][Full Text] [Related]
14. Methylation characteristics and developmental potential of Guangxi Bama minipig (Sus scrofa domestica) cloned embryos from donor cells treated with trichostatin A and 5-aza-2'-deoxycytidine.
Ning SF; Li QY; Liang MM; Yang XG; Xu HY; Lu YQ; Lu SS; Lu KH
Zygote; 2013 May; 21(2):178-86. PubMed ID: 22355002
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.
Primeau M; Gagnon J; Momparler RL
Int J Cancer; 2003 Jan; 103(2):177-84. PubMed ID: 12455031
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.
Chai G; Li L; Zhou W; Wu L; Zhao Y; Wang D; Lu S; Yu Y; Wang H; McNutt MA; Hu YG; Chen Y; Yang Y; Wu X; Otterson GA; Zhu WG
PLoS One; 2008 Jun; 3(6):e2445. PubMed ID: 18560576
[TBL] [Abstract][Full Text] [Related]
17. 8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1.
Zhang Q; Wang Z; Chen X; Qiu H; Gu Y; Wang N; Wang T; Wang Z; Ma H; Zhao Y; Zhang B
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073721
[TBL] [Abstract][Full Text] [Related]
18. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
20. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).
Spiller SE; Ditzler SH; Pullar BJ; Olson JM
J Neurooncol; 2008 Apr; 87(2):133-41. PubMed ID: 18060600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
